ISRCTN10763234已完成未知
Evaluation of the Men A specific antibody persistence in Ghanaian children more than five years after immunization with PsA-TT (2.5 µg, 5 µg, or 10 µg polysaccharide concentration) Long-term follow-up of infants of 14-18 weeks age who participated in clinical trial PsA-TT-004 in Ghana
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1,028
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Enrolled in the initial study intervention group and completed the final blood draw at 36 weeks
- •2. Received at age 12-18 months (inclusive) a single dose of MenAfriVac® during the national campaign in 2012 (new control group)
排除标准
- •1. Any chronic condition or medical/hereditary history suggesting subject would be immuno-compromised (i.e. HIV, autoimmune disease)
- •2. Non-residence in the study area or intent to move out within one year (new control group only)
- •3. Any condition or criteria that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study
研究者
相似试验
招募中
不适用
The seroprevalence of neutralizing antibody against Japanese encephalitis virus in health care workersJapanese encephalitis riskJapanese encephalitisSeroprevalenceSeroepidemiologySerological studyBangkokadultshealthcare workersThailandTCTR20151017004Sanofi Pasteur, Thailand400
Enrolling By Invitation
不适用
The seroprevalence of neutralizing antibody against Dengue virus in health care workersDengue fever riskDenguePRNTNeutralizing antibodySeroprevalenceSeroepidemiologySerological studyBangkokadultshealthcare workersThailandTCTR20160303002Sanofi Pasteur, Thailand402
已完成
不适用
Measurement of antibodies induced to patients with immunosuppressive state or chronic kidney disease by new influenza (A/H1N1) vaccinatiocollagen-vascular diseases, rheumatoid arthritis and chronic kidney diseasesJPRN-UMIN000002754Division of Rheumatology & Clinical Immunology, Jichi Medical University200
尚未招募
不适用
Analysis of Antibody (IgM & IgG) responses among symptomatic adult COVID-19 Positive patients, getting admitted to Odisha COVID Hospital, KIMS, BBSRCTRI/2020/12/030113I
尚未招募
4 期
Antibody persistence at 6 months or more in individuals primed with 2 doses of an inactivated vaccine who received a heterologous or homologous third dose – extension of study RHH_001 and safety and immunogenicity of a 4th dose with recombinant covid-19 vaccine (AstraZeneca/Fiocruz) or mRNA covid-19 vaccine (Comirnaty, Pfizer/ Wyeth)Covid-19C08.730RBR-4b5kzhdInstituto D'Or de Pesquisa e Ensino